Anti-PD-L1 (Avelumab), Human IgG1 Antibody

Anti-PD-L1 (Avelumab), Human IgG1 Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a human IgG1 lambda monoclonal antibody that specifically targets programmed death-ligand 1 (PD-L1). Binding of PD-L1 to the PD-1 and B7.1 receptors occurs on T cells and antigen-presenting cells that results in suppression of cytotoxic T-cell activity, T-cell proliferation, and cytokine production. The antibody binds PD-L1 through the FG loops and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1. This releases the suppression of immune responses and promotes the inhibition of tumor growth. Studies show that the drug is capable of inducing antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. The original drug received FDA approval to treat Merkel cell cancer. It is currently been used in immunotherapy for several cancers

Immunogen Sequence:Human PD-L1

Target Alternative Name:MSB-0010718C, MSB0010682, B7-H, B7H1, B7-H1, CD274, PDCD1L1, PDL1, PD-L1, B7 homolog 1, PDCD1 ligand 1, programmed cell death 1 ligand 1, Programmed death ligand 1

Species Reactivities:Human

Tag Line:The biosimilar is a human IgG1 lambda monoclonal antibody that binds to PD-L1 and inhibits the interaction with PD-1 and promotes anti-tumor immune response

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.